Skip to content

Clinical trials

Recruiting Observational Immunologic Deficiency Syndromes trials

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Immunologic Deficiency Syndromes Phase: Observational Status: Recruiting Clear all

24 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20001
20092
20102
20141
20152
20161
20171
20201
20212
20231
20243
20253
20261

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Recruiting24

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
National Institute of Allergy and Infectious Diseases (NIAID)8
National Cancer Institute (NCI)2
Centre Hospitalier Régional d'Orléans1
Charles University, Czech Republic1
Columbia University1
Henry M. Jackson Foundation for the Advancement of Military Medicine1
Icahn School of Medicine at Mount Sinai1
Institut National de la Santé Et de la Recherche Médicale, France1
Karolinska Institutet1
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)1

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Immunologic Deficiency Syndromes24
Autoimmune Diseases5
Infections5
Primary Immunodeficiency Diseases4
Immune System Diseases3
Asthma2
Hypersensitivity2
Lymphoma2
Myelodysplastic Syndromes2
Acquired Immunodeficiency Syndrome1

Trials

Showing 1 to 24 of 24. Each trial links to its page on Pharma Observatory.

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.